Introduction
AML is a cancer of the haematopoietic stem and progenitor cells resulting in a long-lasting leukaemic stem cell clone that is frequently resistant to standard treatment. [1] [2] [3] [4] Approximately 50% of young patients are either resistant to chemotherapy or relapse after treatment and therefore require additional therapy. 3 Although novel agents such as Flt3 inhibitors and farnesyl transferase inhibitors are currently being investigated, the allogeneic BM SCT has been shown to deliver a sustained graft-vstumour effect against chemotherapy-resistant leukaemic stem cell clones. [4] [5] [6] [7] The benefit of this reduced relapse risk is often negated by significant non-relapse mortality, the major causes being GVHD, infection and diffuse alveolar damage. 4, 8 Reduced-intensity conditioning (RIC) regimens have been developed that allow stable engraftment and low non-relapse mortality allowing allografting to be feasible in older patients. [9] [10] [11] [12] Although these protocols are better tolerated, GVHD and infection remain considerable barriers to successful outcomes.
Immunosuppression aims to decrease lethal GVHD without diminishing the GVL effect. 13 Although this can be achieved with agents such as fludarabine, cyclosporine, methotrexate, methylprednisolone and mycophenolate mofetil, more specific effects can be achieved by targeting the T lymphocytes and DC populations, which are known to play a central role in mediating GVHD and GVL.
14 Antibodies such as alemtuzumab and ALG can directly modulate the functions of these cells both in the recipient and incoming donor graft through differing mechanisms. 15, 16 Alemtuzumab is a monoclonal humanized antibody that binds specifically to the pan-lymphocyte marker CD52. 15, 17, 18 The in vivo administration of alemtuzumab results in profound immunosuppression, significantly reducing GVHD when compared with T-cell replete transplants for a variety of haematological malignancies. 12, 13, [18] [19] [20] [21] [22] [23] [24] [25] Conversely, as a result of the depletion of the lymphocytes and APCs involved in GVL as well as GVHD, alemtuzumab has been associated with increased risk of relapse 26 In addition, alemtuzumab is associated with poor immune recovery post transplant, 26 and it is now apparent that an increased risk of infections after transplant with alemtuzumab is a significant cause of morbidity and mortality. 27, 28 Balancing these competing effects in favour of low non-relapse mortality is the goal of the effective use of alemtuzumab.
Despite the obvious promise of in vivo T-cell depletion with alemtuzumab, there are no prospective studies comparing allografts prepared with and without alemtuzumab for the treatment of AML. In this study, we retrospectively compare outcomes for AML patients treated with RIC sibling allo-SCT after conditioning in the presence or absence of alemtuzumab. In this way, we seek to specifically address the question of the effect of alemtuzumab on RIC sibling allo-SCT for AML.
Patients and methods

Patient and disease characteristics of all patients
All patients reported to the British Society of Blood and Marrow Transplantation (BSBMT) registry database and who have undergone an HLA-identical sibling RIC transplant for AML between June 2000 and December 2004 were selected for the retrospective analysis. Transplant units in the United Kingdom are required to report basic transplant and demographic data to the BSBMT. Eighty-eight patients were identified who fulfilled the eligibility criteria. A further two patients received in vivo T-cell depletion with agents other than alemtuzumab and were therefore not included in this analysis. After initial registration, participating transplant centres are required to provide regular follow-up reports on each patient consisting of GVHD (according to standard criteria 29, 30 ), additional cell therapy, secondary malignancies, relapse and death. All participating transplant centres were contacted to verify the data already held in the database and to provide extra data required to carry out the study. This included information on cytogenetics, conditioning regimens, T-cell depletion, post transplant immunosuppression, acute and chronic GVHD and infections.
Comparison of patient and disease characteristics between the alemtuzumab and no alemtuzumab groups The patient and disease characteristics of the alemtuzumab and no alemtuzumab groups are shown in Table 1 . The median alemtuzumab dose is 60 mg (range 30-100 mg). There is no statistically significant difference in the age and sex of the patients between the two groups. In addition, there is no statistically significant difference in the proportions of patients within each of the MRC karyotypic risk groups between the alemtuzumab and no alemtuzumab groups. Disease karyotype at diagnosis of AML is known to be one of the most important predictors of survival, and equivalence in this characteristic between the two groups adequately controls for this factor. Similarly, disease status at transplant shows equivalence between these groups. In the no alemtuzumab group, 32 patients (86%) were in CR compared with 48 patients (94%) in the alemtuzumab group. Of these patients in CR, 72% of the no alemtuzumab patients were in CR1 compared with 75% of the alemtuzumab patients (P ¼ 0.80). Considering all patients, the overwhelming majority (83 patients, 94%) received fludarabine-based conditioning regimens. Fludarabine was combined with BU, melphalan or CY. There was a statistically significant excess of the fludarabine/melphalan regimen in the alemtuzumab group compared with the no alemtuzumab group. In contrast, fludarabine/CY conditioning is more commonly used in patients who did not receive alemtuzumab. There was no statistically significant difference between the two groups in terms of nucleated cell dose, CD34 dose, sex mismatch and ABO mismatch (data not shown for the latter two variables). Haematopoietic chimerism was determined by a variety of methods including sex chromosome analysis by FISH and PCR for microsatellite repeats. Some centres reported T-lymphocyte chimerism.
The primary outcome measures were overall survival, disease-free survival, relapse risk, non-relapse mortality, total infectious episodes and number of patients experiencing infectious complications before day 100 of transplant.
Statistical analysis
Overall survival and PFS were calculated by KaplanMeier, and comparisons between subsets were made by the log-rank test for binary or non-ordered comparisons and by Cox regression for ordered groups of more than two subsets. The relapse rate and non-relapse mortality rates were calculated together as cumulative incidences using competing risks analysis by the Fine-Gray method. The infection incidence data were compared using Fisher's exact test, whereas continuous variables such as cell doses, recovery times and ages were compared using the nonparametric Mann-Whitney rank-sum test.
Results
Comparison of overall survival, relapse risk and non-relapse mortality between the alemtuzumab and no alemtuzumab groups The overall survival at 5 years for the alemtuzumab and no alemtuzumab groups is 60% (95% confidence interval (CI) 44-73%) and 53% (95% CI 34-68%), respectively (P ¼ 0.85; Figure 1) , with a median follow-up of 27 months (range 3-72 months) and 48 months (range 7-72 months), respectively. The overall survival at 2 years for the alemtuzumab and no alemtuzumab groups is similarly equivalent at 60 and 61%, respectively (P ¼ 0.84). The nonrelapse mortality at 2 years is 12% in the alemtuzumab group and 17% in the no alemtuzumab group (P ¼ 0.49) and 12 and 20%, respectively, at 3 years ( Figure 2) . The relapse rate, however, at 2 years in the patients treated with alemtuzumab is 35% compared with 19% in the group not given alemtuzumab (P ¼ 0.28) and 38 and 30% at 3 years ( Figure 3) . In both groups, relapses tended to occur within the first 2 years.
Acute GVHD occurred in 18 patients (36%) treated with alemtuzumab compared with 12 patients (32%) not treated with alemtuzumab (P ¼ 0.78). Grades II-IV acute GVHD occurred in eight patients (22%) in the no alemtuzumab group compared with seven patients (14%) in the alemtuzumab group, although this difference does not reach statistical significance (P ¼ 0.25). Chronic GVHD occurred in 21 out of 30 (70%) of the evaluable patients not given alemtuzumab, whereas only 10 out of 45 (22%) patients developed it in the alemtuzumab group. Extensive chronic GVHD occurred in 14 out of 30 (47%) patients in the no alemtuzumab group compared with 2 out of 45 (4%) in the alemtuzumab group (P ¼ 0.001). The 3-year chronic GVHD rate is 77% for the no alemtuzumab group compared with 23% in the alemtuzumab group (Po0.0001). Chronic GVHD data was not available in 4 out of the 33 patients (12%) who survived beyond 100 days in the no alemtuzumab group and in 4 out of 49 patients (8%) in the alemtuzumab group. All of the non-relapse mortality in the alemtuzumab group occurs within the first year of transplant, whereas a significant percentage of the non-relapse mortality in the no alemtuzumab group occurs after 1 year.
Comparison of platelet recovery, haematopoietic chimerism and donor lymphocyte infusions between the alemtuzumab and no alemtuzumab groups The time for platelet recovery to 50 Â 10 9 /l was also significantly different between the two groups, with the alemtuzumab-treated patients having a median time of 13 days (0-58) and the no alemtuzumab patients having a median time of 17 days (11-96) (P ¼ 0.03). For the 33 patients in the no alemtuzumab group and the 48 patients in the alemtuzumab group where data are available, 61 and 75% of patients achieved full-donor haematopoiesis at a median time of 224 days (95% CI 106-N) and 97 days (95% CI 61-133), respectively. Two of 31 patients (6%) for whom data were available in the no alemtuzumab group received donor lymphocyte infusions (DLIs). In the alemtuzumab group, however, the DLI usage was significantly higher with 16 of 48 patients (33%) requiring DLIs (P ¼ 0.004).
Comparison of infection rates between the alemtuzumab and no alemtuzumab groups Within the first 100 days after transplant, there was a significantly greater number of infectious complications in the alemtuzumab group compared with the no alemtuzumab group (P ¼ 0.02; Table 2 ). In the alemtuzumab group, 79% of evaluable patients developed infections compared with 57% of patients who developed an infection in the no alemtuzumab group. Out of 77 reports of infection in the alemtuzumab group, 27 were because of CMV, whereas only 7 out of 27 reports of infection in the no alemtuzmab group were because of CMV (P ¼ 0.01). There was a nonsignificant trend towards more bacterial infections in the alemtuzumab group (P ¼ 0.08). Although insufficient for comparison, we note that relatively few fungal infections were reported from either group.
Comparison of overall survival, relapse risk, non-relapse mortality and infection rates between the alemtuzumab and no alemtuzumab groups for patients in CR at transplant For patients in CR at transplant, the overall survival at 2 years is equivalent between the alemtuzumab and no alemtuzumab groups at 68% (P ¼ 0.60). The relapse rate and non-relapse mortality at 2 years for the alemtuzumab and no alemtuzumab groups are 33, 16% (P ¼ 0.29) and 11, 16% (P ¼ 0.43), respectively. Although there remains a trend towards higher relapse risk and lower non-relapse mortality in the alemtuzumab group, this also does not reach statistical significance in this subgroup of patients. Grades II-IV acute GVHD occurred in 7 of 32 (22%) and 5 of 48 (10%) patients in the no alemtuzumab and alemtuzumab groups, respectively (P ¼ 0.284). Twenty four percent (10/42 evaluable) of the patients receiving alemtuzumab and in CR at transplant developed chronic GVHD compared with 80% (20/27 evaluable) not receiving T-cell depletion (Po0.0001). The infection risk in the first 100 days after transplant in patients in CR at transplant is higher for the alemtuzumab group (35/43, 81% evaluable) compared with the no alemtuzumab group (10/20, 50% evaluable) where data are available (P ¼ 0.02).
Comparison of overall survival, relapse risk, non-relapse mortality and infection rates between the alemtuzumab and no alemtuzumab groups for patients receiving fludarabinemelphalan conditioning As the majority of patients in our cohort received fludarabine-melphalan conditioning at transplant, with a relative excess of patients receiving this therapy in the alemtuzumab group, we investigated the effect of alemtuzumab within this large subgroup of patients. The patient demographics in this specific subgroup on a no alemtuzumab vs alemtuzumab basis shows no statistically significant differences in median age, ABO mismatch, CD34 þ cell dose and sex mismatch (data not shown). In the no alemtuzumab group compared with the alemtuzumab group, there was no statistically significant difference (P ¼ 0.40) in the MRC karyotype risk groups: good risk (11 vs 5%), standard risk (72, 86%) and poor risk (17, 8%). The proportion of patients in first CR in the no alemtuzumab and alemtuzumab groups is also equivalent at 60 and 72%, respectively (P ¼ 0.39). The overall survival and PFS at 2 years in the no alemtuzumab and alemtuzumab groups are 65 and 67% (P ¼ 0.87) and 65 and 58% (P ¼ 0.48), respectively. The relapse rate and nonrelapse mortality for no alemtuzumab and alemtuzumab at 2 years are 15 and 28% (P ¼ 0.24) and 20 and 13% (P ¼ 0.61), respectively. Chronic GVHD is 67% (12/18 evaluable) in the no alemtuzumab group compared with 25% (9/36 evaluable) in the alemtuzumab group (Po0.0006).
Discussion
The evidence for the GVL effect in preventing relapse after allo-SCT is now overwhelming. 31 In AML, it has been clearly established that the relapse risk after allo-SCT is lower than that after autologous or syngeneic transplants. 32, 33 The early observation that the development of GVHD correlates inversely with relapse risk suggested overlapping immune-mediated mechanisms between GVHD and GVL. 34 Further pivotal studies showed that T-lymphocyte depletion of grafts dramatically reduces GVHD, but at a cost of elevated relapse risk as a result of the loss of the GVL effect. 35 A major objective in the development of allogeneic transplantation strategies is to reduce GVHD while maintaining GVL and minimizing infectious complications. In this retrospective study, the effect of alemtuzumab as an in vivo T-cell depletion was investigated in the context of sibling RIC allografts for adult AML.
The most striking difference between the alemtuzumab and no alemtuzumab groups is in the pattern of chronic GVHD, which was significantly reduced in those receiving alemtuzumab. Extensive chronic GVHD, a major cause of long-term disability, is virtually absent in those treated with alemtuzumab. Moreover, there are no significant differences in non-relapse mortality and relapse risk between the alemtuzumab and no alemtuzumab groups. Despite a robust effect on chronic GVHD, overall survival is not significantly affected by treatment with alemtuzumab with a plateau in the Kaplan-Meier plot for the patients treated with and without the drug. This is in contrast to earlier studies that have suggested that chronic GVHD predicts for a significant risk reduction for relapse. 36 T-cell-replete allogeneic transplants generally have a lower risk of relapse compared with TCD allografts. Although this is balanced by increased GVHD in the former, in the comparison of the two groups in this study, we are able to report that measures to reduce chronic GVHD do not increase relapse risk sufficiently to decrease overall survival. However, our interpretation of these data should take into account the fact that median follow-up of the alemtuzumab group is much shorter than that of the no alemtuzumab group, and so we cannot exclude the possibility of more relapses with further follow-up in the alemtuzumab group, thereby reducing the overall survival. Consistent with earlier reports, DLI usage was higher in the alemtuzumab group and this may also partly explain the lack of any statistically significant difference in the relapse risk seen in the two groups of patients.
The overall risk of acute GVHD as well as grades II-IV acute GVHD is not significantly different between the two groups of patients. This is counter to the overwhelming evidence that alemtuzumab reduces the incidence of acute GVHD. The explanation for this may relate to a statistically significant excess of the more intensive fludarabine/melphalan regimen in the alemtuzumab group and a similar excess of the less intensive fludarabine/CY regimen in the no alemtuzumab group. Acute GVHD is thought to be caused by the activation of donor T cells in response to host cytokines released by tissue damage caused by the conditioning therapy. 37, 38 The more intensive melphalan regimen may therefore have generated a relative excess of acute GVHD in the alemtuzumab group compared with the CY in the no alemtuzumab group resulting in equivalence in these two groups. A subgroup analysis of patients receiving only fludarabine/melphalan conditioning, however, showed that the effects of alemtuzumab on acute and chronic GVHD seen in the overall analysis were also shown in this specific subgroup. The effects of different conditioning chemotherapies requires further assessment in a prospective randomized trial.
There is much evidence that alemtuzumab causes poor immune reconstitution following allogeneic transplant. 18, [39] [40] [41] Our findings support the previous data and expand further on the groups of pathogens to which transplant recipients are susceptible. These pathogens are often a cause of recurrent hospital admissions that affect not only the quality of life for the patient but also on health resources. Viral infections predominate in the alemtuzumab group, and CMV is the most common organism detected. CMV disease, however, is reported infrequently (data not shown), probably because of routine pre-emptive monitoring. Although prophylactic antibacterial therapy is not the standard of care in the United Kingdom, antifungal prophylaxis is routinely used post transplant. This may be the explanation for the low overall number of reported fungal infections in the first 100 days after transplant.
In conclusion, the retrospective analysis of the registry data shows that alemtuzumab has a beneficial effect on transplantation outcomes by reducing chronic GVHD without affecting overall survival in this cohort of patients with AML. This is achieved at the cost of increased infectious complications. Although these initial results are extremely promising, we have emphasized the retrospective nature of this study and also highlighted potential confounding factors that require further investigation. Enrolment of this group of patients into appropriately powered, prospective randomized, controlled trials are essential before we can recommend the routine use of alemtuzumab in HLA-identical sibling RIC transplantation for AML.
